Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof

A crystal form of a compound represented by formula I or a salt thereof, being one equivalent of mesylate crystal form A of the compound represented by formula I, crystal form D of the compound represented by formula I, one equivalent of maleate crystal form A of the compound represented by formula I, one equivalent of tartrate crystal form C of the compound represented by formula I, one equivalent of citrate crystal form B of the compound represented by formula I, or one equivalent of succinate crystal form D of the compound represented by formula I,

• wherein an X-ray powder diffraction pattern of the one equivalent of mesylate crystal form A of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 10.2973°±0.2°, 14.7185°±0.2°, 15.1407°±0.2°, 17.8003°±0.2°, 18.3418°±0.2°, 20.6191°±0.2°, and 20.7584°±0.2°;
• an X-ray powder diffraction pattern of the crystal form D of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 11.539°±0.2°, 12.658°±0.2°, 13.558°±0.2°, 18.081°±0.2°, 18.859°±0.2°, 20.278°±0.2°, and 23.157°±0.2°;
• an X-ray powder diffraction pattern of the one equivalent of maleate crystal form A of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 5.2344°±0.2°, 10.8375°±0.2°, 12.9364°±0.2°, 17.781°±0.2°, 18.6613°±0.2°, 18.9188°±0.2°, and 20.1186°±0.2°;
• an X-ray powder diffraction pattern of the one equivalent of tartrate crystal form C of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 10.196°±0.2°, 15.543°±0.2°, 15.757°±0.2°, 17.004°±0.2°, 18.196°±0.2°, 20.699°±0.2°, and 21.665°±0.2°;
• an X-ray powder diffraction pattern of the one equivalent of citrate crystal form B of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 10.196°±0.2°, 15.543°±0.2°, 15.757°±0.2°, 17.004°±0.2°, 18.196°±0.2°, 20.699°±0.2°, and 21.665°±0.2°;
• an X-ray powder diffraction pattern of the one equivalent of succinate crystal form D of the compound represented by formula I, measured using Cu—Kα radiation, has at least three, at least four, at least five, at least six, or at least seven characteristic peaks at the following 2θ angles:
• 15.715°±0.2°, 17.778°±0.2°, 18.44°±0.2°, 18.698°±0.2°, 18.86°±0.2°, 20.079°±0.2°, and 20.218°±0.2°.